Breast Cancer News

CHICAGO — The addition of toripalimab to first-line nab-paclitaxel significantly prolonged PFS among patients with PD-L1-positive metastatic or recurrent triple-negative breast cancer, according to results of a phase 3 trial.

CHICAGO — One-year of adjuvant trastuzumab remains the standard-of-care treatment duration for most patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.

CHICAGO — “Committed and collective action” will be required if a key goal of the Cancer Moonshot — reducing cancer mortality by at least 50% in 25 years — will be met, the NCI director told ASCO Annual Meeting attendees.

CHICAGO — During ASCO Annual Meeting, Healio honored our Healio Disruptive Innovators in hematology/oncology in our second annual award ceremony.

CHICAGO — The addition of ribociclib to endocrine therapy improved invasive DFS vs. endocrine therapy alone in patients with hormone receptor-positive, HER2-negative early-stage breast cancer.

A smartphone app-assisted postoperative monitoring intervention improved quality of recovery after cancer surgery, according to results of a study conducted at University of Calgary.

BALTIMORE — A late-breaking session at the ACOG Annual Clinical & Scientific Meeting highlighted FDA updates in breast density reporting that include a lay summarization for patients while ACOG clinical guidance on breast density remains unchanged.

Women with breast cancer whose BMI fell in the overweight or obese ranges achieved meaningful weight loss via a telephone-based intervention, according to phase 3 study results.

Staffing shortages at radiation oncology clinics are causing treatment delays and increased patient anxiety, according to results of a national survey from American Society for Radiation Oncology.

In this episode, host Shikha Jain, MD, speaks with Ken Bloom, MD, FCAP, about developing technologies to assist cancer analysis and pathology, the spatial component of antibody conjugates and more.